What is a "mini-tender" offer?

A mini-tender offer is a type of tender offer where an individual or entity offers to purchase a small percentage of a company's outstanding shares, typically at a price below the current market value. These offers are often made without the company's endorsement and can be confusing for shareholders.

Why is Pfizer warning investors about this offer?

Pfizer is warning investors because the unsolicited mini-tender offer from TRC Capital is at a price lower than the market price and is not endorsed by Pfizer's management. The company wants to protect its shareholders from potentially making a disadvantageous decision by selling their shares at a discount to an unknown third party.

What should I do if I received this offer?

Pfizer strongly recommends that shareholders do not tender their shares in response to TRC Capital's mini-tender offer. If you have already tendered your shares, you have the right to withdraw them before the offer expires on June 14, 2017, by following the instructions in TRC Capital's offering documents.

Is TRC Capital related to Pfizer?

No, Pfizer Inc. states that it is not affiliated or associated in any way with TRC Capital Corporation, its mini-tender offer, or the offer documentation.

PFE 8-K SEC Disclosure — May 25, 2017

Summary

This 8-K filing from Pfizer Inc. (PFE) on May 25, 2017, addresses an unsolicited "mini-tender" offer from TRC Capital Corporation to purchase up to 4,000,000 shares of Pfizer's common stock at $31.60 per share. Pfizer's management has reviewed this offer and explicitly states that the company does not endorse it. The offer price is approximately 4.27% lower than the preceding day's closing price, and the targeted shares represent a very small fraction (0.067%) of the total outstanding shares. Pfizer is advising its shareholders to disregard this unsolicited offer and has recommended that they do not tender their shares. Shareholders who may have already accepted the offer are informed that they can withdraw their shares before the offer's expiration on June 14, 2017, subject to TRC Capital's terms. The company emphasizes its lack of affiliation with TRC Capital or its mini-tender offer. This filing serves as a crucial alert to investors regarding potentially predatory offers targeting their holdings.

Key Highlights

1Pfizer Inc. received notice of an unsolicited "mini-tender" offer from TRC Capital Corporation.
2The offer seeks to purchase up to 4,000,000 shares of Pfizer's common stock at $31.60 per share.
3The offer price is approximately 4.27% below Pfizer's closing stock price on May 12, 2017.
4The targeted shares represent a negligible 0.067% of outstanding common stock.
5Pfizer explicitly states it does not endorse the mini-tender offer.
6Shareholders are strongly advised by Pfizer not to tender their shares.
7Shareholders who have tendered can withdraw their shares before the offer's expiration on June 14, 2017.

PFIZER INC 8-K Report, Corporate Update (May 25, 2017)

Summary

Key Highlights

Frequently Asked Questions